Amylyx Pharmaceuticals (AMLX) Shares Outstanding (Weighted Average) (2021 - 2026)

Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average) history runs 6 years deep, the most recent figure standing at $110.6 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 29.02% year-over-year to $110.6 million; the TTM figure through Mar 2026 stood at $110.6 million (up 29.02% YoY), while the FY2025 annual figure was $94.6 million, up 38.78% from the prior year.
• Shares Outstanding (Weighted Average) was $110.6 million for Q1 2026 at Amylyx Pharmaceuticals, up from $94.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $110.6 million in Q1 2026 to a low of $51.6 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $72.5 million across 5 years, with a median of $67.9 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) soared 805.76% in 2022, then advanced 1.18% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $58.5 million in 2022, then increased by 14.94% to $67.2 million in 2023, then rose by 1.35% to $68.1 million in 2024, then soared by 38.78% to $94.6 million in 2025, then grew by 16.92% to $110.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $110.6 million (Q1 2026), $94.6 million (Q4 2025), and $89.4 million (Q3 2025), per Business Quant data.